BeiGene Plans Global Filing of Zanubrutinib New Indication for First-Line Mantle Cell Lymphoma in Second Half of 2026

Economic Observer Network BeOneBased on positive clinical study results, a new drug application for zanubrutinib in a new lymphoma indication is planned to be submitted.

Product Development Progress:

Based on the positive results from the MANGROVE study, the company plans to submit marketing applications to global regulatory authorities in the second half of 2026 for zanubrutinib in combination with rituximab as a first-line treatment for mantle cell lymphoma (MCL).。

The above content is compiled based on public information and does not constitute investment advice.